PharmaCare coverage is switching from adalimumab (Humira®) and etanercept (Enbrel®) to their biosimilars
Starting Apr. 7, 2021, PharmaCare is switching coverage from patients taking originators adalimumab (Humira®) and etanercept (Enbrel®) to their biosimilars. adalimumab (Humira®) biosimilars:Amgevita®Hadlima®*Hulio®Hyrimoz®*Idacio® etanercept (Enbrel®) biosimilars:Brenzys®Erelzi® *Hadlima and Hyrimoz aren’t currently approved to treat pediatric Crohn’s disease Patients must meet with their prescriber to start the switching process. Between Apr. 7 and Oct. 7, both …